Isofundin

Magnesium chloride hexahydrate, the active ingredient in Isofundin, is an electrolyte solution presented as a solution for injection for intravenous use. It provides essential electrolytes for fluid and electrolyte replenishment in patients requiring resuscitation or electrolyte replacement.

GNH USA supplies Isofundin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Isofundin is used to restore electrolyte balance and intravascular volume in conditions affecting fluid homeostasis.

Electrolyte replacement: restores plasma concentrations of sodium, potassium, calcium and magnesium in patients with deficits. Fluid resuscitation: expands intravascular volume in hypovolemic states such as hemorrhage or severe dehydration. Maintenance therapy: supports ongoing electrolyte balance during postoperative recovery or critical illness.

Isofundin may be associated with infusion‑related reactions and electrolyte disturbances.

Common Side Effects: - Infusion site pain or erythema - Transient increase in serum sodium - Transient increase in serum potassium - Mild nausea

Serious or Rare Side Effects: - Severe hyperkalemia with cardiac arrhythmia - Anaphylactic reaction to solution components - Fluid overload leading to pulmonary edema

Before administering Isofundin, clinicians should observe the following precautions.

Assess electrolyte levels before administration: obtain baseline serum sodium, potassium, calcium and magnesium. Monitor cardiac rhythm during infusion: detect arrhythmias related to electrolyte shifts. Use caution in patients with renal impairment: reduced clearance may exacerbate electrolyte accumulation. Avoid rapid infusion in patients at risk of fluid overload: infuse over recommended time. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Isofundin can interact with other medications that affect electrolyte balance or fluid status.

Major Interactions (Avoid): - Concurrent use of potassium‑sparing diuretics: risk of hyperkalemia - Calcium channel blockers with high calcium load: risk of hypercalcemia - Co‑administration with hypertonic saline solutions: additive sodium overload

Moderate Interactions (Monitor Closely): - Loop diuretics: may increase electrolyte loss, requiring closer monitoring - ACE inhibitors: can alter potassium balance, necessitating serum checks - Beta‑agonists: may shift potassium intracellularly, affecting serum levels